3 result(s) displayed (1 - 3 of 3):

Bristol-Myers proposes $4.5B ImClone acquisition (from Corporate Dealmaker)

Bristol-Myers Squibb Co. has initiated another step on its path from a diversified health and consumer products company to a focused biopharmaceutical firm. On Thursday morning Bristol-Myers chairman and CEO James Cornelius sent a letter to ImClone Systems Inc.'s chairman Carl Icahn about acquiring the company for $60 per...

Posted on July 31, 2008 8:56 AM

Bristol-Myers continues to morph with Kosan buy (from Corporate Dealmaker)

Drug developer Bristol-Myers Squibb Co. made another deal as it tries to focus on its pharmaceutical business, paying a 233% premium for cancer therapeutics company Kosan Biosciences. Bristol is paying $190 million cash hoping Kosan's late-stage drug Hsp90, among others, will come to market and bring in a few hundred...

Posted on May 30, 2008 7:56 AM

Bristol-Myers taps dealmaker as new CFO (from Corporate Dealmaker)

On March 31, Andrew Bonfield, executive vice president and chief financial officer of Bristol-Myers Squibb Co., will relinquish his role to Jean-Marc Huet. Huet (pictured) comes to BMS from the world of baby food. He was the engineer behind Amsterdam-based Royal Numico NV's acquisition strategy and their eventual $16.8 billion...

Posted on March 5, 2008 12:08 PM